Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca’s SLE drug performs well in Phase III trial

pharmaceutical-technologySeptember 03, 2019

Tag: AstraZeneca , SLE , Anifrolumab , autoimmune , disease

PharmaSources Customer Service